

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 June 2018 (07.06.2018)



(10) International Publication Number
WO 2018/100558 A8

(51) International Patent Classification:

C07H 21/00 (2006.01) A61K 31/7084 (2006.01)
C07H 21/02 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2017/057588

(22) International Filing Date:

01 December 2017 (01.12.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2016-234553 01 December 2016 (01.12.2016) JP
2017-107216 30 May 2017 (30.05.2017) JP
62/589,300 21 November 2017 (21.11.2017) US


(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuoku, Osaka-shi, Osaka, 541-0045 (JP).

(72) Inventors: **YOSHIKAWA, Masato**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **SAITOH, Morihisa**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **KATO, Taisuke**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **YOSHITOMI, Yayoi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **SEKI, Tomohiro**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **NAKAGAWA, Yasuo**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **TOMINARI, Yusuke**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **SETO, Masaki**; c/o

Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **SASAKI, Yusuke**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **OKANIWA, Masanori**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **ODA, Tsuneo**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **SHIBUYA, Akito**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **HIDAKA, Kosuke**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **SHIOKAWA, Zenyu**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **MURATA, Shumpei**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **OKABE, Atsutoshi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **NAKADA, Yoshihisa**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **MOCHIZUKI, Michiyo**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **FREEZE, Brian Scott**; 67 Gates St, Unit 1, Boston, Massachusetts 02127 (US). **TAWARAISHI, Taisuke**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **WADA, Yasufumi**; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-0012 (JP). **GREENSPAN, Paul D.**; 8 Overlook Drive, Acton, Massachusetts 01720 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS



(57) Abstract: The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

- (88) Date of publication of the international search report:**
19 July 2018 (19.07.2018)

Date of publication of the revised international search report:
09 May 2019 (09.05.2019)

- (48) Date of publication of this corrected version:**
20 June 2019 (20.06.2019)

- (15) Information about Correction:**
see Notice of 20 June 2019 (20.06.2019)

Previous Correction:
see Notice of 09 May 2019 (09.05.2019)